Research Article

Transcriptional Regulation of *Fucosyltransferase 1* Gene Expression in Colon Cancer Cells

Fumiko Taniuchi, Koji Higai, Tomomi Tanaka, Yutaro Azuma, and Kojiro Matsumoto

Department of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan

Correspondence should be addressed to Koji Higai; koji@phar.toho-u.ac.jp

Received 9 November 2012; Accepted 20 December 2012

Academic Editors: S. Hong and A. Mentese

Copyright © 2013 Fumiko Taniuchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The α 1,2-fucosyltransferase I (FUT1) enzyme is important for the biosynthesis of H antigens, Lewis B, and Lewis Y. In this study, we clarified the transcriptional regulation of FUT1 in the DLD-1 colon cancer cell line, which has high expression of Lewis B and Lewis Y antigens, expresses the *FUT1* gene, and shows α 1,2-fucosyltransferase (FUT) activity. 5'-rapid amplification of cDNA ends revealed a FUT1 transcriptional start site -10 nucleotides upstream of the site registered at NM_000148 in the DataBase of Human Transcription Start Sites (DBTSS). Using the dual luciferase assay, *FUT1* gene expression was shown to be regulated at the region -91 to -81 nt to the transcriptional start site, which contains the Elk-1 binding site. Site-directed mutagenesis of this region revealed the Elk-1 binding site to be essential for FUT1 transcription. Furthermore, transfection of the dominant negative Elk-1 gene, and the chromatin immunoprecipitation (ChIP) assay, supported Elk-1-dependent transcriptional regulation of *FUT1* gene expression in DLD-1 cells. These results suggest that a defined region in the 5'-flanking region of *FUT1* is critical for FUT1 transcription and that constitutive gene expression of *FUT1* is regulated by Elk-1 in DLD-1 cells.

1. Introduction

Incomplete synthesis and neosynthesis are two major factors affecting cancer-associated alterations of cell surface carbohydrate determinants. Expression of sialyl Lewis A/X, NeuAca2,3Gal β 1,3/4(Fuca1,4/3)GlcNAc-R, is accelerated in the advanced stages of cancer by hypoxia-induced transcription of several glycogenes [1–3]. In normal epithelial cells, disialyl Lewis A, NeuAca2,3Gal β 1,3(NeuAca2,6)GlcNAc-R, and sialyl 6-sulfo Lewis X, NeuAca2,3Gal β 1,4 (SO₃-6)GlcNAc-R, are preferentially expressed; they are synthesized by GlcNAc: α 2,6-sialyltransferase (ST6GlcNAc) VI [4] and GlcNAc: β 6-sulfotransferase (6-SulT) [5], respectively.

Blood group A and B antigens expressed on leukocytes and epithelial cells are synthesized by the transfer of GalNAc and Gal to precursor H antigen, Fuca1,2Gal β 1-R, catalyzed by A-transferase and B-transferase and producing A antigen, GalNAca1,3(Fuca1,2)Gal β 1-R, and B antigen, Gal α 1,3(Fuca1,2)Gal β 1-R, respectively. This process is significant during the development, differentiation, and

maturation of normal cells [6]. ABH antigens are deleted or reduced in various cancers including myeloid malignancies [7], leukemia [8], oral cancer [9], and bladder cancer [10]. The A-transferase gene promoter region contains CpG-rich sites whose methylation status correlates well with gene expression; treatment with 5-aza-dC results in the appearance of A-transferase gene and A-antigen expression [11]. The Sd^a blood group carbohydrate structure, GalNAc β 1,4(NeuAca2,3)Gal β 1,4GlcNAc-R, and β 1,4-GalNAc transferase (β 1,4-GalNAcT) II, which is responsible for Sd^a synthesis gene expression, are abundantly expressed in the normal gastrointestinal mucosa, while their expression levels are markedly decreased in gastric and colonic cancers. Treatment of cancer cells with 5-aza-dC induces expression of Sd^a and β 1,4-GalNAcT II and reduces their metastatic potential [12–14].

Loss of H antigen in myeloid malignancies and leukemia [7, 8] and loss of α 1,2-fucosyltransferase (FUT) activities in gastric cancer [15] are common, although the mechanism remains to be elucidated. FUT1 (H enzyme) and FUT2

(Se enzyme) genes are cloned and responsible for synthesis of α 1,2-fucosylation on both core structures of type 1/2, Gal β 1,3/4GlcNAc-R, producing H antigen and Lewis B/Y, Fuc α 1,2Gal β 1,3/4(Fuc α 1,4/3)GlcNAc-R [16, 17]. H antigen, Lewis B, and Lewis Y are expressed in fetal distal colorectal mucosa, but not in adult tissues; they are reexpressed in colorectal carcinoma [18]. The stage- and tissue-specific expression of the *FUT1* gene is regulated by three transcriptional start sites (E1, E2, and E7) and alternative use of multiple promoters [19, 20]. It has been suggested that transcription starts from both E1 and E7 in an undifferentiated colorectal cancer cell line (SW-620); it was dramatically decreased at E1 but not E7 after differentiation of the cells by treatment with butyrate [20].

Here, we show transcriptional regulation of *FUT1* in DLD-1 cells using 5'-rapid amplification of cDNA ends (5'-RACE), a dual luciferase assay for sequential deletion and site-directed mutagenesis, transient overexpression of dominant negative form of Elk-1, and chromatin immunoprecipitation (ChIP) assay. Our results indicate that 5'-flanking regions at positions -91 to -81 nt relative to the *FUT1* gene transcription start site are critical for *FUT1* transcription and mRNA expression in DLD-1 cells.

2. Materials and Methods

2.1. Cells and Cell Culture. Human colorectal DLD-1 and SW48 cells were purchased from the Japanese Collection of Research Bioresources Cell Bank (Tokyo, Japan) and cultured in Dulbecco's modified Eagle's medium (DMEM) (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum (JRC Biosciences, Lenexa, KS, USA) under a humidified atmosphere containing 5% CO₂ at 37°C.

2.2. Flow Cytometry Analysis. The primary mouse antibodies used in this study were obtained from Seikagaku Co. (Tokyo, Japan), including anti-Lewis B (IgG1, 2-25LE) and anti-Lewis Y (IgG3, 12-4LE). For determination of the carbohydrate antigens on the cell surface, cells (5×10^6 cells/mL) were treated with primary antibodies (100 μ L of 1 μ g/mL of each) in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) and 0.1% NaN₃ for 1 h at 37°C and washed three times with 1% BSA/PBS. The cells were further incubated with fluorescein-isothiocyanate- (FITC-) conjugated anti-mouse IgG + IgM goat antibody (100 μ L, 1 μ g/mL) (SouthernBiotech, Birmingham, AL, USA) in 1% BSA/PBS for 1 h at 37°C. After washing three times with 1% BSA/PBS, the cells were subjected to flow cytometry using CytoAce300 (Jasco, Tokyo, Japan).

2.3. Measurement of α 1,2-FUT Activity. α 1,2-FUT activity was determined as described previously [21, 22]. Briefly, the cells were sonicated on ice three times for 10 s in Tris-HCl (10 mM, pH 7.0) containing 1% Triton X-100. After centrifugation, cell lysate (100 μ g protein, 20 μ L) was incubated with 0.5 mM Gal β 1,4GlcNAc, which was aminated and coupled with 2-aminopyridyl- β -alanine (Wako, Osaka, Japan) in the

presence of guanosine 5'-diphospho- α -L-fucose (GDP-Fuc; 0.5 mM; Sigma-Aldrich, St Louis, MO, USA), MgCl₂ (10 mM) in HEPES buffer (100 mM, pH 7.5) for 8 h at 37°C. After the reaction mixture was diluted with distilled water, boiled for 3 min, and centrifuged at 16,000 g for 3 min, an aliquot was injected onto Wakopak Handy ODS (4.5 mm id $\times$ 150 mm, Wako) at 55°C and the product was separated with a 1.0 mL/min flow rate of 2% acetonitrile in ammonium acetate (10 mM). The eluent was monitored by a Model FS-8020 fluorescence detector (Tosoh Co., Tokyo, Japan) at Ex 330 nm and Em 450 nm. The peak areas were calculated using a Model LC-8020 Multi Station (Tosoh).

2.4. RT-PCR. Total RNA was extracted from DLD-1 and SW48 cells using TRIzol reagent (Life Technologies Co., Carlsbad, CA, USA). The first-strand cDNA (20 μ L) was synthesized from total RNA (5 μ g) using ReverTra Ace reverse transcriptase (Toyobo, Tokyo, Japan) and oligo (dT)₂₀ primer, followed by DNase I treatment, according to the manufacturer's instructions. cDNA (0.5 μ L) was amplified in a PC-812 thermal cycler (Astec Co., Fukuoka, Japan) using Go Taq (Promega, Madison, WI, USA) and specific forward and reverse primer sets, according to the manufacturer's instructions. The PCR conditions for *FUT1* were 95°C for 2 min followed by 30 cycles of 98°C for 20 s, 60°C for 5 s, and 72°C for 30 s; for GAPDH we used 20 cycles. The specific forward and reverse primer sets used were as follows: 5'-GCAGCTTCACGACTGGATGTCGGAG-3' and 5'-TACACCACTCCATGCCGTTGCTGGTGACCA-3' for *FUT1*; 5'-CCACCCATGGCAAATTCATGGCA-3' and 5'-TCTAGACGGCAGGTCAGGTCCACC-3' for GAPDH, respectively. Primer sequences were designed using Primer Express software version 2.0.0 (Applied Biosystems, Foster City, CA, USA).

2.5. Determination of the *FUT1* Transcription Start Site in DLD-1 Cells Using 5'-Rapid Amplification of cDNA Ends (5'-RACE). The 5' end of *FUT1* cDNA was amplified with 5'-Full RACE Core Set (Takara Bio Inc., Otsu, Japan) according to the manufacturer's instructions. First-strand cDNA was synthesized from 1 μ g of total RNA using the 5'-phosphorylated *FUT1*-specific primer 5'-GATCGGGGATGCAGGGG-3'. Template mRNA was digested with RNase H at 37°C for 30 min and the cDNA precipitated by the addition of ethanol. The single-strand DNA precipitate was dissolved into the ligation buffer and incubated with T4 ligase at 16°C for 16 h. The concatemer DNA was used as a template for the first PCR amplification, using forward primer 5'-CCTTTGTCTCTGGAGCCG-3' and reverse primer 5'-GGCTAACGTAGGTCCAGCT-3'. PCR conditions were 94°C for 3 min followed by 25 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 60 s. The resulting PCR products were diluted 100-fold with distilled water and amplified under the conditions described above, using the second forward primer 5'-CTCCAGCCTTGGAATGGTT-3' and reverse primer 5'-AACCTGTCTTCCCTCTGGGT-3'. PCR products were ligated into pGL4 vector (Life Technologies) and sequenced using a 3730xl DNA analyzer (Applied Biosystems).

2.6. Deletion Constructs of Plasmids and Luciferase Assay. The 5'-flanking region -700 to +1 nt of the *FUT1* transcriptional start site was amplified from DLD-1-derived genomic DNA by PCR using the forward and reverse primers 5'-AGGTGAGTAGACTCAGGTGGCCTG-3' and 5'-CCCAGGTTCTTTCAGGAGCAC-3', respectively. The PCR products were 5'-phosphorylated using T4 Polynucleotide Kinase (Toyobo) and ligated into pGL4 vector which was digested with *EcoRV* (Toyobo) and alkaline phosphatase from *E. coli* (Toyobo). The sequence was ascertained using a 3730xl DNA analyzer.

Plasmids for pGL4.11/-700.+1, pGL4.11/-419.+1, pGL4.11/-190.+1, pGL4.11/-121.+1, pGL4.11/-100.+1, pGL4.11/-91.+1, and pGL4.11/-81.+1 were constructed by PCR, using pGL4/-700.+1 plasmid as the PCR template, and ligated into pGL4.11 vector. PCR conditions were 94°C for 2 min, followed by 30 cycles of 95°C for 0.5 min, 60°C for 5 min, and 72°C for 1 min. The specific forward primers used were 5'-AAGGATCTGGGGTCTCAAGG-3' (pGL4.11/-419.+1), 5'-AGTATCCTGCCTTGGAGCC-3' (pGL4.11/-190.+1), 5'-ATGCTCAGACCCTGGACATC-3' (pGL4.11/-121.+1), 5'-TGGACATCCCAGCCTCCT-3' (pGL4.11/-100.+1), 5'-AGCCTCCTCCTCCCTGATG-3' (pGL4.11/-91.+1), and 5'-GCAATCCTGGTGTTCCTTCA-3' (pGL4.11/-81.+1), respectively. The specific reverse primer used was 5'-ATCCTCGAGGCTAGCG-3'.

For the *FUT1* promoter assay, 0.2 µg of pGL4.11 constructs and 0.02 µg of pRL-TK-Luc vector (Promega Co., Madison, WI, USA) plasmids were transiently cotransfected into DLD-1 cells ($1-3 \times 10^5$ cells per well) using Lipofectamine 2000 reagent (Life Technologies). The pRL-TK-Luc vector contains the TK promoter 5'-upstream of the *Renilla* luciferase gene. After 24 h, the cells were harvested and lysed. Firefly and *Renilla* luciferase activities were determined using the Dual Luciferase Assay System and 20/20n luminometer (Promega).

2.7. Site-Directed Mutagenesis of *FUT1* Promoter Regions. Site-directed mutagenesis of the 5'-flanking region of the *FUT1* gene was carried out using the KOD-Plus-Mutagenesis Kit (Toyobo), which is based on inverse-PCR. The pGL4.11/-190.+1 plasmid was used as PCR template. Primers used for site-directed mutagenesis were 5'-TCGATTCCTCCCTGATGCAATCCTGGT-3' and 5'-CTGGGATGTCCAGGGTCTGA-3' for -190.+1 mut. PCR was performed according to the manufacturer's instructions. PCR products were digested with *DpnI* and self-ligated with DNA ligase. The recombinant plasmids were transformed into *E. coli* DH5a competent cells (Toyobo) and positive clones were confirmed by DNA sequencing using a 3730xl DNA analyzer. Dual luciferase activities were determined using the Dual Luciferase Assay System and 20/20n luminometer (Promega).

2.8. Transfection of the Dominant Negative Elk-1 Gene. A dominant negative Elk-1 (DN-Elk-1) vector designed for double-mutated Elk-1 S383A and S389A was prepared from Elk-1 vector (Toyobo) by inverse PCR using the KOD-mutagenesis kit according to the manufacturer's instructions.

The DN-Elk-1 expression vector was amplified by PCR using the forward and reverse primers 5'-GTGCCCCGGCCA-AGCTCT-3' and 5'-GGGCGCAATGGGAGCCAGGG-TGCTCCAGAA-3', respectively. Then, 5, 10, and 20 µg of DN-Elk-1 vector was transfected into DLD-1 cells using Lipofectamine 2000 reagent. After 24 h transfection, total RNA was extracted and *FUT1* and *GAPDH* mRNA levels were determined by RT-PCR.

The cDNA (5 µL) was then used for quantitative RT-PCR using TaqMan Gene Expression Assay (Life Technologies), Probe qPCR (Toyobo), and the ABI Prism 7500Fast Detection system (Applied Biosystems) in a 96-well plate according to the manufacturer's instructions. The specific forward and reverse oligonucleotide primers used were assay No. Hs00355741.m1 for *FUT1* and Hs03929097.g1 for *GAPDH*.

PCR conditions were 95°C for 10 min, followed by 40 cycles of 95°C for 30 s, 60°C for 60 s, and 72°C for 60 s. The amount of *FUT1* transcript was determined for each sample and normalized to *GAPDH* levels.

2.9. Chromatin Immunoprecipitation Assay. The chromatin immunoprecipitation assay for the 5'-flanking region of the *FUT1* gene was performed using HaloCHIP System (Promega) according to the manufacturer's instructions. Human Elk-1 full-length cDNA that had been PCR-amplified from Elk-1 vector (Toyobo) was cloned into the pHTC vector (Promega) using the In-Fusion HD Cloning Kit (TaKaRa) with the forward and reverse primer sets 5'-ATT-CCTACCGCGGATATGGACCCATCTGTGACG-3' and 5'-GGCCCAAATCTAGATGGCTTCTGGGGCCCTGGG-3', respectively. The recombinant plasmids were transformed into *E. coli* DH5a competent cells and positive clones were confirmed using a 3730xl DNA analyzer.

DLD-1 cells were seeded at a density of $4-8 \times 10^5$ cells per well of a 6-well plate and then transfected with 30 µg of Halo-tagged Elk-1 expression plasmid using the Neon Transfection System (Life Technologies) with pulse voltage 1150 V, pulse width 30, pulse no 2. After 24 h, the cells were crosslinked with formaldehyde-containing PBS, then lysed in cold Mammalian Lysis Buffer and sonicated on ice six times for 10 s. After centrifuging the sonicated samples at 14,000 g for 5 min, the supernatant was precipitated with HaloLink Resin, washed, and released into supernatant with Reversal Buffer. After the eluted DNA was purified with Wizard SV Gel and PCR Clean up system (Promega), target regions were amplified by PCR using Go Taq (Promega) with specific primers according to the manufacturer's instructions. The specific forward and reverse oligonucleotide primers used were 5'-AACCTCAACCTC-ATCTGTCC-3' and 5'-GGTTCTCTGGTGAAAGAAA-3' for from -140 to -41 nt. of the 5'-flanking region of the *FUT1* gene, and 5'-TGATGTAACTGGGGTCCTT-3' and 5'-TGAGACTCAGGAATGTGGGC-3' for -534 to -424 nt. The PCR conditions were 95°C for 2 min followed by 30 cycles of 98°C for 20 s, 50°C for 10 s and 72°C for 30 s. PCR products were separated by 3% agarose gel electrophoresis and amplified DNAs were detected with ethidium bromide.

FIGURE 1: Expression of Lewis B/Y antigens, α 1,2-FUT activities, and FUT1 mRNA in SW48 and DLD-1 cells. (a) Lewis B and Lewis Y antigens on the surface of SW48 and DLD-1 cells were determined using flow cytometry. (b) α 1,2-FUT activities were determined by HPLC using fluorescent substrate Gal β 1,4GlcNAc-CM. (c) FUT1 mRNA expression levels were determined by RT-PCR. The results were obtained in three independent experiments and data represent mean $\pm$ SD. Asterisks indicate significant differences ($P < 0.05$).

3. Results and Discussion

3.1. Expression of Lewis B and Lewis Y Antigens, α 1,2-FUT Activity, and FUT1 mRNA in DLD-1 and SW48 Cells. To clarify the regulation mechanism of the carbohydrate phenotypes, we determined Lewis B and Lewis Y carbohydrate antigens on two colorectal carcinoma cell lines using flow cytometry. Both Lewis B and Lewis Y antigens were abundantly expressed on DLD-1 cells, while expression levels on SW48 cells were low (Figure 1(a)). The α 1,2-FUT activities responsible for synthesis of these carbohydrate antigens,

determined using fluorescence substrate Gal β 1,4GlcNAc-CM, were low in SW48 cells compared with DLD-1 cells (Figure 1(b)). RT-PCR revealed that FUT1 mRNA expression levels were also increased in DLD-1 cells compared with SW48 cells (Figure 1(c)). These results indicate that FUT1 mRNA expression levels are variable in colorectal cancer cell lines and correlate well with the expression levels of Lewis B and Lewis Y antigens.

3.2. Promoter Activities of Deletion Constructs of the FUT1 5'-Flanking Region. To clarify the highly constitutive expression

FIGURE 2: Nucleotide sequence of the 5'-flanking region of the *FUT1* gene and promoter activities of the *FUT1* reporter gene in DLD-1 cells. (a) Consensus transcription-factor-binding motifs are detectable in the 5'-flanking region of *FUT1*. Nucleotides are numbered relative to the transcription start site obtained from 5'-RACE analysis (i.e., the observed transcription start site was set to +1). (b) *FUT1* promoter deletion constructs and their luciferase activities in DLD-1 cells. Luciferase reported plasmids were constructed from DLD-1 genomic DNA by PCR and ligation. In each case, each plasmid construct and pRL-CMV were cotransfected into DLD-1 cells and luciferase activity was determined in a dual-luciferase assay 24 h after transfection. Firefly luciferase activities were normalized to *Renilla* luciferase activity to correct for differences in transfection efficiency. The results obtained in three independent experiments are expressed as mean $\pm$ SD. Significant differences ($P < 0.05$) are indicated by asterisks.

of the *FUT1* gene in DLD-1 cells, we determined its transcription start site using 5'-RACE, which revealed one major transcript of about 400 bp (data not shown), indicating that the *FUT1* gene was transcribed at the E1 promoter [19, 20]. Based on sequence analysis, this gene product was transcribed -10 nt from the site registered at NM_000148 in the DataBase of Human Transcription Start Sites (DBTSS). The transcription start site and 5'-untranscribed region of *FUT1* genomic DNA are shown in Figure 2(a). A homology search using the Match program (<http://www.gene-regulation.com/index.html>) revealed that the 5'-untranscribed region (-190 to +1) of the *FUT1* gene contained several putative binding sites for transcription factors such as Elk-1, c-Rel, NF- κ B, AREB6, and CREB.

To identify transcriptional regulation of the *FUT1* gene in DLD-1 cells, we prepared *FUT1* promoter deletion constructs using pGL4/-700_+1 as PCR template and ligated them into pGL4.11. After cotransfection of these deletion constructs with pRL-TK-Luc vector into DLD-1 cells, dual luciferase activities were determined (Figure 2(b)). Firefly luciferase activities were markedly decreased on deletion of the -91 to -81 nt region. This region contained a consensus Elk-1 binding site, indicating that transcription of the *FUT1* gene in DLD-1 cells was constitutively regulated by Elk-1.

3.3. Site-Directed Mutagenesis of *FUT VI*. To determine whether Elk-1 can upregulate *FUT1* gene transcription, we

FIGURE 3: Site-directed mutagenesis on *FUT1* promoter and effect of DN-Elk-1 overexpression on expression of *FUT1* mRNA in DLD-1 cells. (a) Mutagenesis in the region -90 to -81 of the *FUT1* promoter. 10 µg of the wild (pGL4.11/-190_-+1_wild) and mutant (pGL4.11/-190_-+1_mut) constructs and 0.5 µg of pRL-CMV were co-transfected into DLD-1 cells and luciferase activity was determined 24 h after transfection. In each case, firefly luciferase activity was normalized to *Renilla* luciferase activity to correct for differences in transfection efficiency. The relative activities of luciferase are normalized to the activities of pGL4.11/-190_-+1_wild as 100. The results obtained in three independent experiments are expressed as mean $\pm$ SD. Significant differences ($P < 0.05$) compared with the equivalent wild-type reporter construct are indicated by asterisks. (b) *FUT1* mRNA expression in DN-Elk-1-transfected cells. After transfection with 5, 10, and 20 µg DN-Elk-1 expression vector, *FUT1* mRNA expression levels in DLD-1 cells were determined by RT-PCR. The results were obtained in three independent experiments and data represent mean $\pm$ SD. Significant differences ($P < 0.05$) compared with non-transfected cells are indicated by asterisks.

FIGURE 4: Chromatin immunoprecipitation analysis of *FUT1* promoter in DLD-1 cells. Chromatin immunoprecipitation (ChIP) analysis for the Elk-1 binding site region within *FUT1* promoter in DLD-1 cells. (a) Primers designed for the 5'-flanking region of *FUT1* (Primer A: -140 to -41, Primer B: -534 to -424). (b) DLD-1 cells transfected with pHTC/Elk-1 vector were precipitated and amplified by PCR with specific primers (see (a)) as described in Section 2. gDNA: positive control; PCR amplification for fragmented and nonprecipitated genomic DNA from DLD-1 cells 24 h after transfection of Halo-tagged Elk-1 gene. Halo ip: PCR amplification for fragmented and precipitated genomic DNA with Halo resin from the DLD-1 cells 24 h after transfection of Halo-tagged Elk-1 gene.

prepared mutated constructs (AGTCGATTCC) of the -90 to -81 nt region. The mutant constructs were then transfected into DLD-1 cells and the luciferase activity of each was determined (Figure 3(a)). In terms of the -186 to -156 nt region (Figure 4(a)), promoter activities of constructs carrying a four-base substitution (pGL4/-190_-+1_mut) were significantly lower than that observed for the unmodified reporter construct (pGL4/-190_-+1_wild). Although this suppression was incomplete, the promoter regions in the -90 to -81 region were important at least for *FUT1* transcription.

3.4. Regulation of *FUT1* Gene Expression by Elk-1. To confirm the transcriptional regulation of *FUT1* gene expression by Elk-1, we used RT-PCR to analyze the effect of overexpression

of dominant negative (DN)-Elk-1 on *FUT1* mRNA level. Phosphorylation at S383 and S389 of Elk-1 is essential for its transcriptional activity [23]. We transfected the DN-Elk-1, mutated S383A and S389A into DLD-1 cells and determined *FUT1* mRNA expression using RT-PCR. *FUT1* mRNA expression in DLD-1 cells was suppressed in a dose-dependent manner by 48 h transfection of the DN-Elk-1 gene (Figure 3(b)). These results indicate that constitutive *FUT1* mRNA expression in DLD-1 cells is transcriptionally regulated by Elk-1.

3.5. Binding of the Elk-1 to the Promoter of *FUT1*. To clarify whether Elk-1 regulates *FUT1* mRNA expression, we determined its binding to the promoter of *FUT1* using the

ChIP assay (Figure 4). We selected two primers, primer A for the promoter region of the 5'-flanking region of the *FUT1* gene and primer B for -534 to -424 nt (Figure 4(a)). Cells transfected with Halo-tagged Elk-1 gene were collected and the proteins cross-linked to the DNA, sonicated, and precipitated with Halo-resin. After the isolated DNA was amplified with PCR, the DNA bound to Elk-1 was visualized. Although the promoter region (-140 to -41) containing the Elk-1 binding site was precipitated with Elk-1, the *FUT1* 5'-flanking region (-534 to -424), with no Elk-1 binding site, was not (Figure 4(b)).

In this report, we have confirmed that the transcriptional start site of *FUT1* is located -10 nucleotides upstream of the site registered at NM_000148, and that constitutive expression of the *FUT1* gene is transcriptionally regulated by Elk-1, as confirmed by transfection of the DN-Elk-1 gene, site-directed mutagenesis, and the ChIP assay in DLD-1 cells. Expression of the ETS-like transcription factor Elk-1 gene is regulated by TATA box and the Erg-1 binding site, which functions specifically in monocytes [24]. Many glycosyltransferase genes have been reported to be regulated by Est family transcription factors, including GlcNAcT V [25–30], FUT4 [31], GalT I [32], GalT V [33], ST3Gal IV [34], and ST6GalNAc I [35].

Increased expression of α 1,2-fucosylated glycans on the surface of rat colon carcinoma cells on transfection with the *FUT1* gene is associated with tumorigenicity and an increased resistance to apoptosis [36] and lymphokine activated killer cytotoxicity, but not to natural killer cell lysis [37]. Suppression of *FUT1* and *FUT4* gene expression by the short interfering RNA technique reduces Lewis Y expression and inhibits cell proliferation by decreasing the epidermal growth factor receptor signaling pathway and cancer growth [38]. Transfection of the *FUT1* gene in tumor cells selectively inhibits sialyl Lewis X and binding to E-selectin without affecting synthesis of sialyl Lewis A and binding to P-selectin [39, 40].

In tumor cells, incomplete synthesis of glycans results in reduced A and B blood antigens [7–11], disialyl Lewis A and sialyl 6-sulfo Lewis X antigens [41, 42] and Sd^a antigen [12–14] accompanied by the appearance or increase of H antigen, sialyl Lewis A and sialyl Lewis X antigens, and T, Tn and sialyl Tn antigens [3, 43]. Hypermethylation in the promoter region is involved in downregulation of A/B transferase [9, 11], ST6GlcNAc VI [41] and 6-SulT [42]. We also demonstrated in SW48 cells that many glycosyltransferase genes were downregulated, and that 5-aza-dC treatment enhanced FUT2, FUT4, FUT6, C2GnT, ST3Gal I, ST3Gal II, and ST3Gal IV mRNA expression (data not shown). However, epigenetic regulation of carbohydrate antigen synthesis in cancer cells would be more complicated.

In this report, we have suggested that the constitutive gene expression of *FUT1* is regulated at 5'-flanking regions at positions -91 to -81 nt of *FUT1* and that *FUT1* gene expression is upregulated by Elk-1 in DLD-1 cells. Further studies are needed to clarify the mechanism of expression of cancer-associated carbohydrate antigens with respect to direct regulation of glycosyltransferase genes and indirect regulation through expression of transcriptional factors.

Conflict of Interests

The authors declare no conflict of interests. The authors alone are responsible for the content of the paper.

References

- [1] R. Kannagi, "Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression—the Warburg effect revisited," *Glycoconjugate Journal*, vol. 20, no. 5, pp. 353–364, 2004.
- [2] R. Kannagi, "Carbohydrate antigen sialyl Lewis a—its pathophysiological significance and induction mechanism in cancer progression," *Chang Gung Medical Journal*, vol. 30, no. 3, pp. 189–209, 2007.
- [3] R. Kannagi, J. Yin, K. Miyazaki, and M. Izawa, "Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants—Hakomori's concepts revisited," *Biochimica et Biophysica Acta*, vol. 1780, no. 3, pp. 525–531, 2008.
- [4] A. Tsuchida, T. Okajima, K. Furukawa et al., "Synthesis of disialyl Lewis a (Lea) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of α -series gangliosides," *Journal of Biological Chemistry*, vol. 278, no. 25, pp. 22787–22794, 2003.
- [5] N. Kimura, C. Mitsuoka, A. Kanamori et al., "Reconstitution of functional L-selectin ligands on a cultured human endothelial cell line by cotransfection of α 1 $\rightarrow$ 3 fucosyltransferase VII and newly cloned GlcNAc β :6-sulfotransferase cDNA," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 8, pp. 4530–4535, 1999.
- [6] S. I. Hakomori, "Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer," *Biochimica et Biophysica Acta*, vol. 1473, no. 1, pp. 247–266, 1999.
- [7] T. Bianco, B. J. Farmer, R. E. Sage, and A. Dobrovic, "Loss of red cell A, B, and H antigens is frequent in myeloid malignancies," *Blood*, vol. 97, no. 11, pp. 3633–3639, 2001.
- [8] T. Bianco-Miotto, D. J. Hussey, T. K. Day, D. S. O'Keefe, and A. Dobrovic, "DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients," *PLoS One*, vol. 4, no. 3, Article ID e4788, 2009.
- [9] E. Dabelsteen and S. Gao, "ABO blood-group antigens in oral cancer," *Journal of Dental Research*, vol. 84, no. 1, pp. 21–28, 2005.
- [10] Y. Chihara, K. Sugano, A. Kobayashi et al., "Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene," *Laboratory Investigation*, vol. 85, no. 7, pp. 895–907, 2005.
- [11] Y. Kominato, Y. Hata, H. Takizawa, T. Tsuchiya, J. Tsukada, and F. I. Yamamoto, "Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region," *Journal of Biological Chemistry*, vol. 274, no. 52, pp. 37240–37250, 1999.
- [12] Y. I. Kawamura, R. Kawashima, R. Fukunaga et al., "Introduction of Sda carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis," *Cancer Research*, vol. 65, no. 14, pp. 6220–6227, 2005.
- [13] Y. I. Kawamura, M. Toyota, R. Kawashima et al., "DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer," *Gastroenterology*, vol. 135, no. 1, pp. 142–151, 2008.

- [14] H. R. Wang, C. Y. Hsieh, Y. C. Twu, and L. C. Yu, "Expression of the human Sda β -1,4- N-acetylgalactosaminyltransferase II gene is dependent on the promoter methylation status," *Glycobiology*, vol. 18, no. 1, pp. 104–113, 2008.
- [15] E. V. Chandrasekaran, J. Xue, C. Piskorz et al., "Potential tumor markers for human gastric cancer: an elevation of glycan:sulfotransferases and a concomitant loss of α 1,2-fucosyltransferase activities," *Journal of Cancer Research and Clinical Oncology*, vol. 133, no. 9, pp. 599–611, 2007.
- [16] R. D. Larsen, L. K. Ernst, R. P. Nair, and J. B. Lowe, "Molecular cloning, sequence, and expression of a human GDP-L-fucose: β -D-galactoside 2- α -L-fucosyltransferase cDNA that can form the H blood group antigen," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 87, no. 17, pp. 6674–6678, 1990.
- [17] R. J. Kelly, S. Rouquier, D. Giorgi, G. G. Lennon, and J. B. Lowe, "Sequence and expression of a candidate for the human Secretor blood group α (1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype," *Journal of Biological Chemistry*, vol. 270, no. 9, pp. 4640–4649, 1995.
- [18] T. F. Orntoft, P. Greenwell, H. Clausen, and W. M. Watkins, "Regulation of the oncodevelopmental expression of type 1 chain ABH and Lewisb blood group antigens in human colon by α -2-L-fucosylation," *Gut*, vol. 32, no. 3, pp. 287–293, 1991.
- [19] Y. Koda, M. Soejima, and H. Kimura, "Structure and expression of H-type GDP-L-fucose: β -D-galactoside 2- α -L-fucosyltransferase gene (FUT1): two transcription start sites and alternative splicing generate several forms of FUT1 mRNA," *Journal of Biological Chemistry*, vol. 272, no. 11, pp. 7501–7505, 1997.
- [20] Y. Koda, M. Soejima, and H. Kimura, "Changing transcription start sites in H-type α (1,2)fucosyltransferase gene (FUT1) during differentiation of the human erythroid lineage," *European Journal of Biochemistry*, vol. 256, no. 2, pp. 379–387, 1998.
- [21] K. Higai, D. Masuda, Y. Matsuzawa, T. Satoh, and K. Matsumoto, "A fluorometric assay for glycosyltransferase activities using sugars aminated and tagged with 7-hydroxycoumarin-3-carboxylic acid as substrates and high performance liquid chromatography," *Biological and Pharmaceutical Bulletin*, vol. 22, no. 4, pp. 333–338, 1999.
- [22] K. Higai, K. Shibukawa, S. Muto, and K. Matsumoto, "Targeted proteo-glycomics analysis of Sialyl Lewis X antigen expressing glycoproteins secreted by human hepatoma cell line," *Analytical Sciences*, vol. 19, no. 1, pp. 85–92, 2003.
- [23] G. Buchwalter, C. Gross, and B. Wasyluk, "Ets ternary complex transcription factors," *Gene*, vol. 324, no. 1-2, pp. 1–14, 2004.
- [24] U. Lehmann, P. Brocke, J. Dittmer, and A. Nordheim, "Characterization of the human elk-1 promoter. Potential role of a downstream intronic sequence for elk-1 gene expression in monocytes," *Journal of Biological Chemistry*, vol. 274, no. 3, pp. 1736–1744, 1999.
- [25] R. Kang, H. Saito, Y. Ihara et al., "Transcriptional regulation of the N-acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC-T1) is mediated by Ets-1," *The Journal of Biological Chemistry*, vol. 271, no. 43, pp. 26706–26712, 1996.
- [26] P. Buckhaults, L. Chen, N. Fregien, and M. Pierce, "Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene," *Journal of Biological Chemistry*, vol. 272, no. 31, pp. 19575–19581, 1997.
- [27] M. Pierce, P. Buckhaults, L. Chen, and N. Fregien, "Regulation of N-acetylglucosaminyltransferase V and Asn-linked oligosaccharide β (1,6) branching by a growth factor signaling pathway and effects on cell adhesion and metastatic potential," *Glycoconjugate Journal*, vol. 14, no. 5, pp. 623–630, 1997.
- [28] J. H. Ko, E. Miyoshi, K. Noda et al., "Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines," *Journal of Biological Chemistry*, vol. 274, no. 33, pp. 22941–22948, 1999.
- [29] H. Yamamoto, J. Swoger, S. Greene et al., " β 1,6-N-acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity," *Cancer Research*, vol. 60, no. 1, pp. 134–142, 2000.
- [30] A. K. Chakraborty, J. de Frietas Sousa, D. Chakraborty et al., "GnT-V expression and metastatic phenotypes in macrophage-melanoma fusion hybrids is down-regulated by 5-Aza-dC: evidence for methylation sensitive, extragenic regulation of GnT-V transcription," *Gene*, vol. 374, no. 1-2, pp. 166–173, 2006.
- [31] D. A. Withers and S. I. Hakomori, "Human α (1,3)-fucosyltransferase IV (FUTIV) gene expression is regulated by Elk-1 in the U937 cell line," *Journal of Biological Chemistry*, vol. 275, no. 51, pp. 40588–40593, 2000.
- [32] X. Zhu, J. Jiang, H. Shen et al., "Elevated β 1,4-galactosyltransferase I in highly metastatic human lung cancer cells: identification of EIAF as important transcription activator," *Journal of Biological Chemistry*, vol. 280, no. 13, pp. 12503–12516, 2005.
- [33] T. Sato and K. Furukawa, "Sequential action of Ets-1 and Sp1 in the activation of the human β -1,4-galactosyltransferase V gene involved in abnormal glycosylation characteristic of cancer cells," *Journal of Biological Chemistry*, vol. 282, no. 38, pp. 27702–27712, 2007.
- [34] A. Taniguchi, M. Hioki, and K. Matsumoto, "Transcriptional regulation of human Gal β 1,3GalNAc/Gal β 1, 4GlcNAc α 2,3-sialyltransferase (hST3Gal IV) gene in testis and ovary cell lines," *Biochemical and Biophysical Research Communications*, vol. 301, no. 3, pp. 764–768, 2003.
- [35] N. Kurosawa, S. Takashima, M. Kono et al., "Molecular cloning and genomic analysis of mouse GalNAc α 2,6- sialyltransferase (ST6GalNAc I)," *Journal of Biochemistry*, vol. 127, no. 5, pp. 845–854, 2000.
- [36] C. Goupille, S. Marionneau, V. Bureau et al., " α 1,2fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells," *Glycobiology*, vol. 10, no. 4, pp. 375–382, 2000.
- [37] S. Marionneau, V. Bureau, C. Goupille et al., "Susceptibility of rat colon carcinoma cells to lymphokine activated killer-mediated cytotoxicity is decreased by α 1, 2-fucosylation," *International Journal of Cancer*, vol. 86, no. 5, pp. 713–717, 2000.
- [38] Z. Zhang, P. Sun, J. Liu et al., "Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth," *Biochimica et Biophysica Acta*, vol. 1783, no. 2, pp. 287–296, 2008.
- [39] M. Zerfaoui, M. Fukuda, V. Sbarra, D. Lombardo, and A. El-Battari, " α (1,2)-fucosylation prevents sialyl Lewis x expression and E-selectin-mediated adhesion of fucosyltransferase VII-transfected cells," *European Journal of Biochemistry*, vol. 267, no. 1, pp. 53–60, 2000.
- [40] S. Mathieu, M. Prorok, A. M. Benoliel et al., "Transgene expression of α (1,2)-fucosyltransferase-I (FUT1) in tumor cells selectively inhibits sialyl-Lewis x expression and binding to E-selectin without affecting synthesis of sialyl-Lewis a or binding to P-selectin," *American Journal of Pathology*, vol. 164, no. 2, pp. 371–383, 2004.
- [41] K. Miyazaki, K. Ohmori, M. Izawa et al., "Loss of disialyl Lewis_x, the ligand for lymphocyte inhibitory receptor sialic

acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis x expression on human colon cancers," *Cancer Research*, vol. 64, no. 13, pp. 4498–4505, 2004.

- [42] M. Izawa, K. Kumamoto, C. Mitsuoka et al., "Expression of sialyl 6-sulfo Lewis X is inversely correlated with conventional sialyl Lewis X expression in human colorectal cancer," *Cancer Research*, vol. 60, no. 5, pp. 1410–1416, 2000.
- [43] Y. S. Kim and G. Deng, "Aberrant expression of carbohydrate antigens in cancer: the role of genetic and epigenetic regulation," *Gastroenterology*, vol. 135, no. 1, pp. 305–309, 2008.